18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: A systematic review and meta-analysis

Nuclear Medicine Communications

Volumn 35, Issue 7, 2014, Pages 697-703

  Lu, Yu Yu ^a   Chen, Jin Hua ^e   Liang, Ji An ^b,d   Chu, Shannon ^f   Lin, Wan Yu ^a,d   Kao, Chia Hung ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Radiation Oncology ^*  (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

PET CT; small cell lung cancer; staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LUNG TUMOR; MULTIMODAL IMAGING; PROCEDURES; RADIOGRAPHY; SCINTISCANNING; SMALL CELL LUNG CANCER;

FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SMALL CELL LUNG CARCINOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902267172     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000122     Document Type: Review

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973; 4:31-42.
3. Stahel RA, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J, et al. Staging and prognostic factors in small cell lung cancer; a consensus report. Lung Cancer 1989; 5:119-126. (Pubitemid 20053516)
4. Tas F, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol 1999; 38:1011-1015. (Pubitemid 30033021)
5. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET-CT) for tumor staging in solid tumors: Comparison with CTand PET. J Clin Oncol 2004; 22:4357-4368. (Pubitemid 41185156)
6. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in the evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44:1200-1209. (Pubitemid 39655178)
7. Schö der H, Larson SM, Yeung HW. PET/CT in oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45:72S-81S.
8. Cohade C, Osman M, Leal J,Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44:1797-1803. (Pubitemid 39663312)
9. Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003; 76:861-866. (Pubitemid 37100761)
10. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 2003; 123: 137S-146S. (Pubitemid 36135711)
11. Hicks RJ, Kalff V, MacManus MP,Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001; 42:1605-1613. (Pubitemid 33131318)
12. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koë ter GH, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000; 343:254-261. (Pubitemid 30490393)
13. Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 2002; 359: 1388-1393.
14. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49:480-508. (Pubitemid 351355215)
15. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. 18F FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: A metaanalysis. Clin Nucl Med 2011; 36:553-559.
16. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: Data-analytic approaches and some additional considerations. Stat Med 1993; 12:1293-1316. (Pubitemid 23230833)
17. Kang S, Kim SK, Chung DC, Seo SS, Kim JY, Nam BH, et al. Diagnostic value of (18)F-FDG PET for evaluation of para-aortic nodal metastasis in patients with cervical carcinoma: A meta-analysis. J Nucl Med 2010; 51:360-367.
18. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
19. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153: 417-421. (Pubitemid 26026883)
20. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67:790-797. (Pubitemid 29207699)
21. Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57:328-333. (Pubitemid 47285426)
22. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: Preliminary experience. Am J Clin Oncol 2004; 27:164-171. (Pubitemid 38455428)
23. Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, et al. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: Preliminary results. Eur J Nucl Med Mol Imaging 2003; 30:1266-1269. (Pubitemid 37205382)
24. Zhao DS, Valdivia AY, Li Y, Blaufox MD. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 2002; 32:272-275. (Pubitemid 35332973)
25. Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, et al. FDGPET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483-488. (Pubitemid 32260915)
26. Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer: A preliminary study. Chest 2001; 119:950-954. (Pubitemid 32197670)
27. Chin R Jr, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: A preliminary study. Lung Cancer 2002; 37:1-6. (Pubitemid 34621450)
28. Kamel EM, Zwahlen D,Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003; 44:1911-1917. (Pubitemid 40022136)
29. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003; 30:78-84. (Pubitemid 36692896)
30. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: A prospective study. J Clin Oncol 2004; 22:3248-3254. (Pubitemid 41103679)
31. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31:1614-1620. (Pubitemid 40104607)
32. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007; 30:45-50. (Pubitemid 46213824)
33. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: Comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18:338-345. (Pubitemid 46323103)
34. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008; 9:30-34. (Pubitemid 351251598)
35. Azad A, Chionh F, Scott AM, Lee ST, Berlangieri SU, White S, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010; 12:443-451.
36. Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med 2011; 25: 406-413.
37. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: A systematic review and cost analysis in the Australian setting. J Thorac Oncol 2012; 7:1015-1020.
38. Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging 2012; 11:253-258.
39. Thomson D, Hulse P, Lorigan P, Faivre-Finn C. The role of positron emission tomography in management of small cell lung cancer. Lung Cancer 2011; 73:121-126.
40. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054-3060. (Pubitemid 34791094)
41. Turrisi AT III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271. 18F-FDG PET in small-cell lung cancer Lu et al. 703 (Pubitemid 29063268)